Bioassay-guided fractionation of a methanol extract of Ganoderma lucidum gave a pure cholesterol esterase inhibitor. On the basis of spectroscopic analysis and comparison with data from the literature, the structure of this compound was identified as 5α,8α-epidioxyergosta-6,22-dien-3β-ol (compound I). This compound inhibited cholesterol esterase activity with an IC 50 value of 42 µM. Lineweaver-Burk plot analysis revealed that compound I is a noncompetitive inhibitor. The findings of this study suggest that compound I may be the active principle of the hypocholesterolemic effect of Ganoderma lucidum.
Cholesterol absorption has a significant impact on plasma cholesterol levels [6] . However, the process of cholesterol absorption has yet to be completely defined at the molecular level. Dietary cholesterol consists of free and esterified cholesterol, the ratio of which depends on the source. The precise physiological function of cholesterol esterase (CEase; E.C. 3.1.1.13) in free cholesterol absorption has been controversial [5, 10] . However, the correlation between the absorption of dietary cholesteryl ester and CEase activity has been unequivocally established [1, 2] . Hydrolysis of cholesteryl ester to cholesterol by CEase in the intestinal lumen is an essential process in the absorption of dietary cholesteryl ester [9] . Indeed, findings from animal studies have shown that inhibitors of CEase efficiently limit the absorption of dietary cholesterol esters [13] . Direct evidence of the involvement of CEase comes from a report on the impaired absorption of cholesterol administered as cholesterol esters in CEase gene knockout mice [8] . CEase is also reported to be involved directly in the regulation of serum cholesterol level; the enzyme has a phospholipase A 2 activity in the hydrolysis of phosphatidyl choline to lysophosphatidyl choline, which is required for the formation of intestinal micelles that facilitate free cholesterol delivery [11, 18] . Thus, inhibitors of CEase may limit the bioavailability of dietary cholesterol derived from cholesterol esters, suggesting a worthwhile strategy for the treatment of hypercholesterolemia and atherosclerosis.
In the course of screening for cholesterol esterase inhibitors from natural sources, an active compound was isolated from the fungus Ganoderma lucidum (G. lucidum). This mushroom has been used in East Asia for the treatment of various diseases and has recently attracted much attention on account of its biological activities [3, 17] . The present paper describes the isolation and characterization of the CEase inhibitor from G. lucidum.
Dried fruiting bodies of G. lucidum from the Yangpyung area were purchased from a local Oriental medicine market in Seoul, Korea. Ground fruiting bodies were extracted with methanol at room temperature by maceration. The resultant extract showed potent cholesterol esterase inhibitory activity.
The enzyme assay was performed as previously described [7] . The convenient substrate p-nitrophenylbutyrate was used for the assay of enzyme activity. Assays were performed in sodium phosphate buffer (0.1 M, pH 7.0) containing 6 mM taurocholate and 10 mM p-nitrophenylbutyrate in the presence or absence of samples. Reactions were initiated by the addition of enzyme [porcine pancreatic cholesterol esterase (Sigma) 160 mU] and the reaction mixture was incubated at 37 o C for 30 min. The reaction was terminated by the addition of 1 ml of ethanol. Using a spectrophotometer, the amount of liberated p-nitrophenol was determined from the absorbance at 405 nm. Three sets of data were collected for each sample concentration. A molar extinction coefficient of 16,300 M -1 cm -1 for pnitrophenol was used to calculate the amount of product formed. Percentage inhibition was calculated by the formula *Corresponding author Phone: +82-2-940-7171; Fax: +82-2-919-0345; E-mail: sdkim@skuniv.ac.kr (A−B)/A×100, where A is the amount of p-nitrophenol resulting from enzymatic hydrolysis in the absence of the inhibitor, and B is that in the presence of the inhibitor. The mode of enzyme inhibition was determined from the Lineweaver-Burk plot.
Bioactivity-guided fractionation of the methanol extract of G. lucidum (1.5 kg) led to the isolation of compound I. Combined extracts were concentrated in vacuo to yield a brown residue (23 g), which was partitioned between water and ethyl acetate. The ethyl acetate layer was dried over anhydrous MgSO 4 , evaporated, and subjected to silica gel column chromatography. The column was eluted with a solvent mixture of petroleum ether-ethyl acetate (9:1-3:1, stepwise) to yield 12 fractions. The active fraction (F7, 410 mg) was concentrated and further purified by Sephadex LH-20 column chromatography using a CH 3 OHCHCl 3 (1:1) mixture. The active compound I crystallized from methanol as white needles. Its purity was monitored by thin layer chromatography (TLC). The TLC plate (Kieselegel 60 F 254 ; Merck) was developed using n-hexaneethylacetate [4, 12, 14] , the active constituent was identified as 5α,8α-epidioxyergosta-6,22-dien-3β-ol (Fig. 1) .
Compound I inhibited CEase in a concentrationdependent fashion with an IC 50 of 42 µM (Fig. 2) . When CEase was incubated with an amount of compound I capable of causing 90% inhibition of enzyme activity, followed by removal of the compound I on a PD 10 desalting column (Pharmacia, Piscataway, NJ, USA), nearly all of the enzyme activity was recovered. This result demonstrated that the inhibition of CEase by compound I was completely reversible. The inhibition mode of compound I was found to be noncompetitive by a Lineweaver-Burk double reciprocal plot of reaction velocity versus substrate concentration (Fig. 3) , in which the K m was the same at different inhibitor concentrations.
Previously, 5α,8α-epidioxyergosta-6,22-dien-3β-ol was isolated from various species of mushrooms, and its wide spectrum of biological effects, including antitumor, DNA topoisomerase I inhibitory, and immunosuppressive activities, has been demonstrated [15, 16] . However, the cholesterol 
